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Two current major research topics in nuclear 
medicine are in the development of long-lived 
positron-emitting nuclides for imaging tracers 
with long biological half-lives and in 
theranostics, imaging nuclides which have a 
chemically analogous therapy isotope. As shown 
in TABLE 1, the radioisotopes of arsenic (As) are 
well suited for both of these tasks with several 
imaging and therapy isotopes of a variety of 
biologically relevant half-lives accessible through 
the use of small medical cyclotrons. The five 
naturally abundant isotopes of germanium are 
both a boon and challenge for the medical nu-
clear chemist. They are beneficial in that they 
facilitate a wide array of producible radioarsenic 
isotopes. They are a challenge as monoisotopic 
radioarsenic production requires isotopically-
enriched targets that are expensive and of lim-
ited availability. This makes it highly desirable 
that the germanium target material is reclaimed 





(% nat. abun.) 
Application 
70As 53 min 
70Ge(p,n) 
(20.4 %) PET 
71As 65.3 h 
70Ge(d,n) 
(20.4 %) PET/SPECT 
72As 26.0 h 
72Ge(p,n) 
(27.3 %) PET 
73As 80.3 d 
73Ge(p,n)  
(7.8 %) Auger therapy 
74As 17.8 d 
74Ge(p,n) 
(36.7 %) PET 




TABLE 1. Properties of radioarsenic isotopes 
 
One major factor which has limited the devel-
opment of radioarsenic has been difficulties in 
its incorporation into biologically relevant tar-
geting vectors. Previous studies have labeled 
antibodies and polymers through covalent bond-
ing of arsenite (As(III)) with the sulfydryl 
group1,2,3. Recent work in our group has shown 
the facile synthesis and utility of superparamag-
netic iron oxide nanoparticle- (SPION-)bound 
radioarsenic as a dual modality positron emis-
sion tomography (PET)/magnetic resonance 
imaging (MRI) agent4. 
Presently, we have built upon previous stud-
ies producing, isolating, and labeling untargeted 
SPION with radioarsenic4,5. We have incorpo-
rated the use of isotopically-enriched 72GeO2
 for 
the production of radioisotopically pure 72As.  
The bulk of the 72GeO2 target material was re-
claimed from the arsenic isolation chemical 
procedure for reuse in future irradiations. The 
72As was used for ongoing development toward 
the synthesis of targeted, As-SPION-based, dual-
modality PET/MRI agents. 
 
Material and Methods 
Targets of ~100 mg of isotopically-enriched 
72GeO2 (96.6% 
72Ge, 2.86% 73Ge, 0.35% 70Ge, 
0.2% 74Ge, 0.01% 76Ge, Isoflex USA) were 
pressed into a niobium beam stop at 225 MPa, 
covered with a 25 µm HAVAR containment foil, 
attached to a water-cooling target port, and 
irradiated with 3 µA of 16.1 MeV protons for 2–3 
hours using a GE PETtrace cyclotron. After irra-
diation, the target and beam stop were assem-
bled into a PTFE dissolution apparatus, where 
the 72GeO2 target material was dissolved with 
the addition of 2 mL of 4 M NaOH and subse-
quent stirring. After dissolution was completed, 
the clear, colorless solution was transferred to a 
fritted glass column and the bulk 72GeO2 was 
reprecipitated by neutralizing the solution with 
the addition of 630 µL [HCl]conc, filtered, and 
rinsed with 1 mL [HCl]conc. To the combined 
72As-
containing filtrates, 100 µL 30% H2O2 was added 
to ensure that 72As was in the nonvolatile As(V) 
oxidation state. The ~3 mL solution was then 
evaporated at 115 ˚C while the vessel was 
purged with argon, followed by a second addi-
tion of 100 µL H2O2 after the volume was re-
duced to 1 mL. When the filtrate volume was 
~0.3 mL, the vessel was removed from heat, 
allowed to cool with argon flow, and the arsenic 
reconstituted in 1 mL [HCl]conc and loaded onto a 
1.5 mL bed volume Bio-Rad AG 1×8, 200–400 
mesh anion exchange column preconditioned 
with 10 M HCl. The radioarsenic was eluted in 
10 M HCl in the next ~10 mL, with 90% of the 
activity eluting in a 4 mL fraction. The column 
was then eluted with 5 mL 1 M HCl. The 72As-rich 
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10 M HCl fraction was reduced to As(III) with the 
addition of ~100 mg CuCl, and heating to 60 ˚C 
for 1 hour. The resulting AsCl3 was then extract-
ed twice into 4 mL cyclohexane, which were 
combined and back extracted into 500 µL of 
water as As(OH)3. 
This solution of 72As in H2O was then used 
directly to label SPION and for subsequent ex-
periments conjugating 72As-SPION with TRC105, 
an angiogenesis-marking monoclonal antibody 
(MAb) targeting endoglin/CD105. Several meth-
ods were initially attempted involving directly 
conjugating the surface-modified SPION to the 
MAb through a polyethylene glycol (PEG) linker. 
More recent studies have investigated the radi-
oarsenic labeling of SPION encapsulated in hol-
low mesoporous silica nanoparticles 
(SPION@HMSN) and its subsequent conjugation 
to TRC105. 
 
Results and Conclusion 
Irradiation of pressed, isotopically-enriched 
72GeO2 resulted in a production yield for 
72As of 
17 ± 2 mCi/(µA·hr·g) and for 71As of 0.37 ± 
0.04 mCi/(µA·hr·g), which are 64 % and 33 %, of 
those predicted from literature6, respectively. 
However, these production yields are in agree-
ment with those scaled from observed produc-
tion yields using analagous natGeO2 targets. The 
end-of-bombardment 72As radionuclidic purity 
can be improved by minimizing the 
72Ge(p,2n)71As reaction by degrading the beam 
energy. A 125 µm Nb containment foil would 
degrade impinging protons to 14.1 MeV and is 
predicted to reduce 71As yield by a factor of 
three, while only reducing 72As yield by 1 %6, 
improving end-of-bombardment radionuclidic 
purity from 98 % to greater than 99 %. 
Overall decay-corrected radiochemical yield 
of the 72As isolation procedure from 72GeO2 
were 51 ± 2 % (n = 3) in agreement with those 
observed with natGeO2 57 ± 7 % (n = 14). The 
beam current was limited to 3 µA as higher cur-
rents 4–5 µA exhibited inconsistent dissolution 
and reprecipitation steps, resulting in an overall 
yield of 44 ± 21 % (n = 6). Dissolution time also 
played an important role in overall yield with at 
least one hour necessary to minimize losses in 
these first two steps. The separation procedure 
effectively removed all radiochemical contami-
nants and resulted in 72As(OH)3 isolated in a 
small volume, pH~4.5 water solution. Over the 
course of minutes to hours after back extraction, 
rapid auto-oxidation to 72AsO4H3 was observed. 
The bulk 72GeO2 target material, which was re-
claimed from the isolation procedure, is being 
collected for future use. 
The synthesis of a targeted PET/MRI agent 
based on the functionalization of 72As-SPION has 
proved to be a difficult task. Experiments conju-
gating 72As-SPION to TRC105 through a PEG 
linker were unsuccessful, despite the investiga-
tion of a variety bioconjugation procedures. 
Current work is investigating the use of 
SPION@HMSN, which have a similar affinity for 
72As as unencapsulated SPION. This new class of 
72As-labeled SPION@HMSN has a hollow cavity 
for potential anti-cancer drug loading, as well as 
the mesoporous silica surface, which may facili-
tate the efficient conjugation of TRC105 using a 
well-developed bioconjugation technique.  
In summary, radioarsenic holds potential in 
the field of diagnostic and theraputic nuclear 
medicine. However, this potential remains 
locked behind challenges related to its produc-
tion and useful in vivo targeting. The present 
work strives to address several of these chal-
lenges through the use of enriched 72GeO2 target 
material, a chemical isolation procedure that 
reclaims the bulk of the target material, and the 
investigation of new targeted nanoparticle-
based PET/MRI agents. 
 
References 
1. M. Jennewein, M. A. Lewis, D. Zhao, E. Tsyganov, 
N. Slavine, J. He, L. Watkins, V. D. Kodibagkar, S. 
O'Kelly, P. Kulkarni, P. P. Antich, Al Hermanne, F. 
Rösch, R. P. Mason, P. E. Thorpe: Clin. Cancer Res. 
14, pp. 1377–1385, 2008. 
2. M. Jahn, V. Radchenko, D. Filosofov, H. Hauser, M. 
Eisenhut, F. Rösch, M. Jennewein: Radiochim. Acta 
98, pp. 807–812, 2010. 
3. M. M. Herth, M. Barz, M. Jahn, R. Zentel, F. Rösch: 
Bioorg. Med. Chem. Lett. 20, pp. 5454–5468, 
2010. 
4. F. Chen, P. A. Ellison, C. M. Lewis, H. Hong, Y. 
Zhang, S. Shi, R. Hernandez, M. E. Meyerand, T. E. 
Barnhart, W. Cai: Angew. Chem. Int. Ed. 52, pp. 
13319–13323, 2013. 
5. P. A. Ellison, T. E. Barnhart, J. W. Engle, R. J. Nick-
les O. T. DeJesus: AIP Conf. Proc. 1509, pp. 135–
140, 2012. 
6. I. Spahn, G. F. Steyn, F. M. Nortier, H. H. Coenen, 
S. M. Qaim: Appl. Radiat. Isot. 65, pp. 1057–1064, 
2007. 
7. F. Chen, H. Hong, Y. Zhang, H. F. Valdovinos, S. Shi, 
G. S. Kwon, C. P. Theuer, T. E. Barnhart, and W. 
Cai: ACS Nano 7, pp. 9027–9039, 2013. 
 
Acknowledgements 
Portions of this work were supported by the U.S. 
Department of Energy under Grant DE-
SC0005281 and DE-SC0008384 and National 
Institutes of Health Grant T32CA009206. 
